Los Angeles Capital Management & Equity Research Inc. raised its stake in shares of Johnson & Johnson (NYSE:JNJ) by 0.7% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,012,879 shares of the company’s stock after purchasing an additional 6,629 shares during the period. Johnson & Johnson accounts for about 0.7% of Los Angeles Capital Management & Equity Research Inc.’s portfolio, making the stock its 16th biggest position. Los Angeles Capital Management & Equity Research Inc.’s holdings in Johnson & Johnson were worth $122,903,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other hedge funds also recently modified their holdings of JNJ. Financial Gravity Wealth Inc. purchased a new stake in shares of Johnson & Johnson in the first quarter worth approximately $105,000. WP Advisors LLC purchased a new stake in shares of Johnson & Johnson in the second quarter worth approximately $108,000. FNY Investment Advisers LLC purchased a new stake in shares of Johnson & Johnson in the second quarter worth approximately $117,000. Live Your Vision LLC raised its holdings in shares of Johnson & Johnson by 58.3% in the second quarter. Live Your Vision LLC now owns 1,363 shares of the company’s stock worth $172,000 after buying an additional 502 shares during the period. Finally, Signition LP purchased a new stake in shares of Johnson & Johnson in the first quarter worth approximately $204,000. Institutional investors and hedge funds own 66.60% of the company’s stock.
Shares of NYSE:JNJ opened at $145.34 on Friday. Johnson & Johnson has a 52-week low of $118.62 and a 52-week high of $148.32. The company has a market capitalization of $388.35 billion, a P/E ratio of 18.21, a PEG ratio of 2.26 and a beta of 0.58. The company has a current ratio of 1.72, a quick ratio of 1.40 and a debt-to-equity ratio of 0.46.
Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Tuesday, October 16th. The company reported $2.05 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.03 by $0.02. Johnson & Johnson had a return on equity of 34.62% and a net margin of 1.89%. The company had revenue of $20.35 billion for the quarter, compared to analysts’ expectations of $20.05 billion. During the same quarter in the prior year, the firm earned $1.90 earnings per share. Johnson & Johnson’s revenue was up 3.6% compared to the same quarter last year. As a group, equities research analysts predict that Johnson & Johnson will post 8.16 earnings per share for the current fiscal year.
The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 11th. Investors of record on Tuesday, November 27th will be paid a $0.90 dividend. The ex-dividend date is Monday, November 26th. This represents a $3.60 annualized dividend and a yield of 2.48%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 49.32%.
JNJ has been the topic of several recent analyst reports. Credit Suisse Group increased their price target on Johnson & Johnson from $149.00 to $152.00 and gave the stock an “outperform” rating in a report on Wednesday, October 17th. Wells Fargo & Co reiterated an “outperform” rating and issued a $160.00 price target on shares of Johnson & Johnson in a report on Friday, September 14th. Citigroup increased their price objective on Johnson & Johnson from $137.00 to $148.00 and gave the stock a “neutral” rating in a research note on Monday, October 22nd. Jefferies Financial Group set a $145.00 price objective on Johnson & Johnson and gave the stock a “buy” rating in a research note on Sunday, July 15th. Finally, Raymond James increased their price objective on Johnson & Johnson from $144.00 to $149.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 17th. Two analysts have rated the stock with a sell rating, eight have issued a hold rating and nine have assigned a buy rating to the company. The stock presently has an average rating of “Hold” and an average target price of $142.54.
In other Johnson & Johnson news, CAO Ronald A. Kapusta sold 7,899 shares of the stock in a transaction on Friday, September 7th. The stock was sold at an average price of $137.18, for a total transaction of $1,083,584.82. Following the sale, the chief accounting officer now owns 25,725 shares of the company’s stock, valued at approximately $3,528,955.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, COO Michael E. Sneed sold 29,000 shares of the stock in a transaction on Monday, August 27th. The shares were sold at an average price of $134.80, for a total value of $3,909,200.00. Following the sale, the chief operating officer now directly owns 59,124 shares in the company, valued at approximately $7,969,915.20. The disclosure for this sale can be found here. In the last three months, insiders sold 85,340 shares of company stock worth $11,992,396. 0.22% of the stock is owned by insiders.
Johnson & Johnson Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Read More: What is a stock buyback?
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.